Organizations have a wealth of unstructured data that most AI models can’t yet read. Preparing and contextualizing this data ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Graphs are everywhere. From technology to finance, they often model valuable information such as people, networks, biological pathways and more. Often, scientists and technologists need to come up ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

The debate about AI’s impact on consulting tends to swing between two extremes: Some argue that AI will render consultants obsolete; others claim it will only make them more indispensable. Both views ...

In the race to develop artificial intelligence, tech giants are building data centers that guzzle up water. That has led to problems for people who live nearby. In the race to develop artificial ...

Forbes contributors publish independent expert analyses and insights. Randy Bean is a noted Senior Advisor, Author, Speaker, Founder, & CEO. Visa (NYSE: V), a world leader in digital payments, is ...